• Ucore recently announced the closing of the first tranche of its previously announced private placement offering of units of the company
• On June 6, the company announced that the U.S. DOD had awarded it a $4 million project grant
• Together, these moves bolster Ucore’s working capital and continue to stamp its position as a leader in its space
• Through its investments, Ucore is inching closer to taking over the global rare earth elements market, which is expected to hit $5.6 billion by 2025

Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), a company engaged in the exploration for and separation and scalable production of rare earth elements (“REEs”) in Canada and the U.S., is, through its many strategic efforts, building itself to become a major leader in its sector. Just recently, the company announced the closing of the first tranche of its previously announced private placement offering of units of the company, for aggregate gross proceeds of $4,409,500, in what is set to be a key catalyst in advancing its RapidSX(TM) REE commercial demonstration plant in Kingston, Ontario (https://ibn.fm/kcaNI).

“We believe that Ucore’s Kingston, Ontario, Demo Plant is currently the largest heavy REE separation plant in North America,” noted Mike Schrider, Ucore’s Vice President.

“It is capable of processing tens of tons of light and heavy REEs utilizing the exact same equipment – and represents a unique technological advantage,” he added (https://ibn.fm/Xn03z).

On June 6, Ucore announced that the U.S. Department of Defense (“DOD”) had awarded it a $4 million project grant. The move showed that Ucore and RapidSX(TM) could meet government benchmarks, even as the company continues establishing an alternative supply chain for REEs independent of the People’s Republic of China (https://ibn.fm/9LEFE). This, coupled with the first tranche private placement, not only bolsters Ucore’s working capital but also continues to stamp its position as a leader in its space.

China controls over 36.7% of the world’s REE reserves, 63% of its mining capacity, and over 90% of its refining capacity. Ucore is out to eat into this market share and assert dominance and independence from this supply chain (https://ibn.fm/k7qM4). Through its tried technology, the company has won over the U.S. government. With its aggressive yet strategic investments, the company is on track to create a critical metals (“CM”) supply chain independent of China.

So far, Ucore has invested over C$35 million to establish and validate the Bokan-Datson Ridge resource. Its additional investments throughout North America continue to inch the company closer to taking over the global rare earth elements market, which is expected to be valued at $5.6 billion by 2025. In addition, these investments continue to prop Ucore to be the leading global metal separation products and services provider, ultimately creating value for its shareholders.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• Recent report projects estimated growth of tellurium market at CAGR of 3.41% between 2022 and 2027
• Growth is tied to increased demand from the consumer electronics industry
• Company’s unique approach offers significant advantages over larger mines

With recent market projections showing steady growth in the tellurium market (https://ibn.fm/11Lg4), First Tellurium’s (CSE: FTEL) (OTCQB: FSTTF) small-mine, phased-approach strategy is sure to strengthen the company’s position in the growing space.

“The tellurium market is estimated to grow at a CAGR of 3.41% between 2022 and 2027,” a 2023 Technavio analysis study reported. “The size of the market is forecast to increase by 83.72 MT.” The report went on to take a closer look at the tellurium market based on application (solar panels, thermoelectric production, metallurgy and others), type (pure tellurium and telluride), and geography (APAC, North America, Europe, South America, and the Middle East and Africa).

“The increased demand from the consumer electronics industry is notably driving market growth,” stated the report. “Tellurium alloys are commercially used in various consumer electronics products. They offer potential solutions to a wide range of applications such as mobile phones, LED displays and projectors, wearable electronic devices, gaskets and lighting, and rollers.

“Additionally, factors such as the increasing urban population, rise in disposable income, strong supply chain and high internet penetration also drive the growth of the global market,” the report continued. “Furthermore, the governments of many developing countries are providing exemptions on certain duties to boost the manufacturing capacity of consumer electronics manufacturers. Therefore, the high demand for this product will drive market growth during the forecast period.”

First Tellurium has worked hard to become a leader in this space. The company’s strategy is to start with a small mine and expand it over time (https://ibn.fm/jkOsq). The company is currently North America’s leading tellurium explorer with its Klondike tellurium-gold property in Colorado and polymetallic Deer Horn Project in British Columbia.

“A key driver of this strategy is Indigenous support, including potential investment and employment,” the company states on its website, noting that its unique approach offers significant advantages over larger mines, including lower exploration/development costs, significantly lower CapEx (only $28.3 million), faster time to production and cash flow, and exceptional post-tax payback (1.6 years). In addition, First Tellurium is able to deliver faster to buyers, has potential dilution-free funding for resource development along with a more simple permitting with a small mine application and a smaller environment footprint.

First Tellurium’s business model is designed to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in Indigenous territory with sustainable exploration. “This is the future of mineral exploration: generating revenue by exploring responsibly and leveraging diverse partnerships,” the company stated. “First Tellurium proudly adheres to and supports the principles and rights set out in the United Nations Declaration on the Rights of Indigenous Peoples and in particular the fundamental proposition of free, prior and informed consent.”

For more information, visit the company’s website at www.FirstTellurium.com.

NOTE TO INVESTORS: The latest news and updates relating to FSTTF are available in the company’s newsroom at https://ibn.fm/FSTTF

• In June 2023, Renovaro announced that a potential IND application for its innovative cancer platform is on track for early 2024 FDA submission
• The company in March 2023 announced proof-of-concept for its proprietary technology to treat pancreatic tumors
• In August 2023, Renovaro announced its entry into a Letter of Intent to merge with GEDi Cube International Ltd. with the aim of accelerating diagnosis, enhancing treatment effectiveness, discovering new therapies, and expanding access to life-saving technologies for cancer and other diseases
• As of August 2023, Renovaro has raised total cash of $82.7 million
• The company’s IP portfolio covering gene and gene-modified cell therapies includes patents, patent applications and licensed technologies under patent application

Renovaro BioSciences (NASDAQ: RENB) formerly Enochian BioSciences Inc., is an advanced, pre-clinical biotechnology firm in cell, gene and immunotherapy focused on solid tumors with short life expectancy. The company aims to unlock potentially long-term or life-long cancer remission in some of the deadliest cancers, and to potentially treat or cure serious infectious diseases such as Human Immunodeficiency Virus (“HIV”) and Hepatitis B Virus (“HBV”) infection.

The oncology platform is now at the forefront of Renovaro’s development activities. While Renovaro’s current efforts focus primarily on pancreatic cancer, it plans to include other solid tumors with short life-expectancy in the first in human Phase I/IIa studies that are on track to start by mid-2024. The company’s Pre-Investigational New Drug (pre-IND) submission included a human study plan covering pancreatic cancer, as well as other cancers that are difficult to treat, potentially including triple-negative breast cancer, head and neck cancers and mesothelioma.

Renovaro’s proprietary, novel technology uses cell- and gene-therapy to promote a renewed immune response against solid tumors. Important confirmatory results from two humanized mouse models using the company’s novel dendritic cell-based therapy, independently conducted by Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy at UCLA, were presented previously at two scientific conferences and were the foundation supporting a pre-IND submission to the U.S. Food and Drug Administration. Notably, Dr. Jewett’s findings from these studies consistently demonstrated 80% to 90% pancreatic tumor reduction in size and weight that was correlated with significant enhancement of key aspects of the immune response.

Renovaro is headquartered in Los Angeles, California.

RENB-DC11

Renovaro’s product development strategy is anchored in the use of “non-self” or allogeneic cells that enhance targeted immune response. Its lead candidate, RENB-DC11, is an innovative therapeutic vaccination platform that could potentially be used to induce life-long remissions from some of the deadliest solid tumors.
Treatment with RENB-DC11 has now been shown to significantly reduce the size of human pancreatic tumors in humanized mice in three independent studies. The reduction in tumor size correlated with statistically significant increases in key components of an immune response.

Pre-IND was completed in June 2023, with IND filing forecast for first half of 2024. First in-human Phase I/IIa trials are predicted shortly after in H1 of 2024, including pancreatic and other solid tumors with poor treatment options and life-expectancy.

Renovaro believes that RENB-DC11 could represent the most promising and effective strategy to achieve life-long remission for a number of common and deadly tumors.

Other Development Candidates

In addition to its lead oncology platform, Renovaro’s development pipeline includes a platform targeting infectious diseases, including:

• RENB-HV12 – An engineered allogeneic T-Cell vaccine, this therapeutic HIV vaccine candidate enhances immune infiltration, immune killing and immune surveillance. Potential pre-IND submission is planned for first half of 2024, with IND-submission expected in second half of 2024.
• RENB-HV21 – Leveraging allogeneic NK plus Gamma Delta T (“GDT”) cells as potential therapy for HIV, ENOB-HV21 shows promising preliminary results without confounding factors. Renovaro owns an exclusive license and has completed the Pre-IND submission, with a potential IND submission and human trials expected in 2024.
• RENB-HV01 – Caring Cross, a non-profit corporation, has shown that its proprietary CAR-T cells cure HIV in a mouse model. Studies in humans have begun. Renovaro has entered into a profit-sharing sublicense with Caring Cross and would share in profits if the product is commercialized.
• RENB-HB01 – This therapeutic approach aims to eliminate all HBV rapidly (“seek and kill”) with a two to three dose treatment regimen. It is expected to be applicable for early disease to maximize impact with low risk of toxicity. Pre-IND comments have been received from the FDA for its AAV-delivery system.
  LOI to Merge with GEDi Cube International Ltd.

On August 9, 2023, Renovaro announced its execution of a binding, exclusive letter of intent to merge a subsidiary with cutting-edge health AI company GEDi Cube International Ltd. The combined company is expected to create a potential multiplier effect to accelerate earlier diagnosis, more effective therapy, and precision in silico drug discovery.

GEDi Cube’s innovative technology, developed over nearly a decade, has already validated earlier diagnoses of lung cancer in humans at a leading university hospital. GEDi Cube has likewise created the early diagnosis technology for 12 additional cancers, including pancreatic and breast cancer.

“I believe joining forces with GEDi Cube could enhance the efficacy of our upcoming trials and speed up the discovery of novel treatment approaches, thereby extending our life-saving technology to more cancer patients and renewing hope for them and their families,” Dr. Mark Dybul, CEO of Renovaro, stated in the news release.

GEDi Cube is led by CEO Craig Rhodes, who brings to that company tremendous industry experience leading life sciences groups at industry leaders Intel, Oracle and NVIDIA.

Market Opportunity

Pancreatic cancer alone is diagnosed globally in approximately 495,000 people each year, including roughly 64,000 in the U.S. Nearly 466,000 of those patients die annually, including approximately 51,000 in the U.S. Because of limited treatment options, life expectancy is very poor – with an approximately 10% patient survival rate at five years after diagnosis.

The global pancreatic cancer treatment market was valued at $2.15 billion in 2021 and is projected to grow from $2.48 billion in 2022 to $6.85 billion by 2029, according to Fortune Business Insights. That growth represents a CAGR of 15.7% for the forecast period.

A separate report from Fortune Business Insights projects that the global HIV drug market will grow from $30.46 billion in 2021 to $45.58 billion in 2028, recording a CAGR of 5.9% over the forecast period.

According to GlobalData, the value of the market for hepatitis B treatment is forecast to experience a significant increase in the coming years, with revenues expected to grow from $1.6 billion in 2022 to $10.5 billion in 2029. That represents a very rapid CAGR of 30% over the period. An estimated 296 million people suffer from the condition worldwide.

Management Team

Dr. Mark Dybul is the CEO of Renovaro. He has served as a tenured professor in the Department of Medicine at Georgetown University Medical Center since June 2017. He also served as Faculty Co-Director of the Center for Global Health and Quality from 2017-2021. Dr. Dybul has worked on HIV and public health for nearly 30 years as a clinician, scientist, teacher and administrator, including as an architect and eventually the Global Ambassador of the U.S. President’s Emergency Plan for AIDS Relief and the Executive Director of the Global Fund to Fight AIDS, Tuberculosis and Malaria from 2013 through May of 2017, and as the co-director of the Global Health Law Program at the O’Neill Institute for National and Global Health Law from 2009 through 2012. He is a member of the U.S. National Academy of Medicine.

Luisa Puche is the company’s CFO. She has served as a senior accounting and financial advisor and president of Puche Group LLC from 2015-2019. She served in various key executive roles, including Interim Chief Accounting Officer, at Brightstar Corp., a $10 billion global wireless device services provider. Ms. Puche began her career at Ernst & Young, where she served for approximately 10 years. Leveraging her broad global audit, advisory and corporate expertise, she has provided strong cross-functional leadership experience managing small and large projects for both publicly traded and privately held companies in various industries, including a global implementation of the latest revenue recognition accounting standard for Del Monte, as well as the global implementation of their SOX-404 program.

Francois Binette, Ph.D., is the Chief Operating Officer and Executive Vice President of Research & Development at Renovaro. He has over 25 years of product development expertise in Advanced Therapies and Regenerative Medicine. His broad industry experience spans a wide range of serious medical conditions, from orthopedics to ophthalmology, CNS and immuno-oncology. His career includes positions at Genzyme, Biosyntech, the DePuy Franchise of Johnson and Johnson, Medtronic and Lineage Cell Therapeutics. He received his Ph.D. from Laval University in Québec, followed by post-doctoral training at the Sanford-Burnham Institute in La Jolla and Harvard Medical School in Boston.

For more information, visit the company’s website at www.EnochianBio.com.

NOTE TO INVESTORS: The latest news and updates relating to RENB are available in the company’s newsroom at https://ibn.fm/RENB

• Trailing-Twelve-Month (“TTM”) Revenue increased by 106% YoY to $25.5 million from $12.4 million in the prior 12-month period, outpacing the global industry average by 10x
• TTM EBITDA increased to $2.5 million from -($0.25) million in the prior 12-month period
• The company’s Q2 2023 revenue increased by 141% YoY to $7.7 million
• The company has seen a high YoY quarterly revenue growth trend: Q3 2022 – 102%; Q4 2022 – 69%; Q1 2023 – 109%
• SuperCom’s recurring revenue represents 73% of total revenue
• Approximately $200 million in EU contracts up for award in the upcoming 18 months
• Over 65% win rate in national government tender in the EU
• High entry barriers, requiring 5-10 years of specific industry experience, with only 10 global players
• More than $40m invested in the research and development of the PureSecurity suite

SuperCom (NASDAQ: SPCB) provides secured solutions for the e-government, IoT and cybersecurity sectors. Since 1988, the company has been a trusted global provider of traditional and digital identity offerings, providing cutting-edge electronic and digital security solutions to governments and organizations, both private and public, around the world.

SuperCom’s mission is to revolutionize the public safety sector worldwide through proprietary electronic monitoring technology, data intelligence, and complementary services.

The company is headquartered in Tel Aviv, Israel, with offices in California and other regions in the U.S.

Business Units

IoT and Connectivity

SuperCom IoT products and solutions provide advanced electronic monitoring solutions and services to criminal justice agencies, enabling customers to detect unauthorized movement of people, vehicles, and other monitored objects. The company provides an all-in-one, field-proven PureSecurity offender monitoring suite, accompanied by services such as GPS monitoring, home detention, domestic violence prevention, and more. The company’s services are specifically tailored to meet each client’s needs.

SuperCom’s proprietary PureSecurity suite of hardware, connectivity, and software components is the foundation for its criminal justice services and offerings. SuperCom is leveraging its extensive technology expertise to implement groundbreaking artificial intelligence (“AI”) technologies into various parts of its core offerings. By leveraging the power of AI, SuperCom’s PureSecurity platform can offer new abilities, such as amplified data analysis, predictive modeling, and streamlined automation – all geared toward optimizing decision-making and operational efficiency.

Competitive advantages of SuperCom’s technology include:

• Long Battery Life (No Tag Charging Required)
• Ultra Lightweight Form Factor
• Next-Gen Location Tech
• Protection of Domestic Violence Victims
• And More

Cybersecurity

In 2015, SuperCom identified the cybersecurity market as a fast-growing space with significant advantages due to synergistic technologies and a shared customer base with its e-Gov and IoT business units. Consequently, SuperCom strategically acquired Prevision Ltd., a company with a strong presence in the market and a broad range of competitive cybersecurity services.

During the first quarter of 2016, SuperCom acquired Safend Ltd., an international provider of cutting-edge endpoint data protection guarding against corporate data loss and theft through content discovery and inspection, encryption methodologies, and comprehensive device and port control.

Both acquisitions significantly expanded the breadth of the company’s global cybersecurity capabilities.

e-Gov

Through proprietary e-government platforms and innovative solutions for traditional and biometrics enrollment, personalization, issuance, and border control services, SuperCom has helped governments, and national agencies design and issue secured multi-identification, or Multi-ID, documents and robust digital identity solutions to their citizens, visitors, and lands.

The company has focused on expanding its activities in the traditional identification, or ID, and electronic identification, or e-Gov, markets, including the design, development, and marketing of identification technologies and solutions to governments in Europe, Asia, America, and Africa using SuperCom’s e-Government platforms.

Market Opportunity

Data from Berg Insight estimates the market for electronic monitoring solutions will grow from $1.2 billion in 2021 to $2.1 billion in 2026, marking a CAGR of 10.8% for the forecast period.

High recidivism rates, prison overcrowding, and soaring incarceration costs are some factors that are driving the electronic monitoring of offenders’ market growth.

An analysis by ReportLinker forecasts that the global cybersecurity market will grow from an estimated value of $173.5 billion in 2022 to $266.2 billion by 2027, achieving a CAGR of 8.9% for the period.

The increased number of data breaches worldwide, the ability of malicious actors to operate from anywhere in the world, the links between cyberspace and physical systems, and the difficulty of reducing vulnerabilities and consequences in complex cyber networks are some factors driving the cybersecurity market growth.

Management Team

Ordan Trabelsi is President and CEO of SuperCom. He has over 15 years of experience as CEO, growing high-tech companies globally. He also has experience in research and development and product innovation, as well as hands-on experience in cybersecurity, encryption, advanced mathematics, and mobile and internet network technologies. Prior to joining SuperCom, he served as co-founder and CEO of Klikot Inc., a global social networking company. He holds an MBA from Columbia University and a B.Sc. in Computer Engineering from The Technion: Israel Institute of Technology.

Barak Trabelsi is COO of SuperCom. He has expertise in big data, cyber, mobile, and internet network technologies, as well as extensive experience in product development and strategies. Prior to joining SuperCom, he served as Senior Product Manager at Equinox Ltd. Before that, he served for four years as VP of R&D at Sigma Wave, a wireless, security, and internet-focused company. He holds a B.Sc. in Computer Science and Business, as well as an MBA from Tel Aviv University.

Gil Alfi is VP of Sales at Safend Ltd., SuperCom’s cybersecurity subsidiary. He joined SuperCom in 2016 as VP of Business Development for Safend. He has more than 18 years of experience in technology companies. He served as an R&D team technology lead for more than seven years and as Director of Product Management for various telecom and wireless companies for more than 10 years. Prior to joining SuperCom, he served as Regional Sales Director at Safend, managing sales regions in Europe and Africa. He holds a B.Sc. in Computer Science and Mathematics and an M.Sc. in Computer Science from Bar-Ilan University.

For more information, visit the company’s website at www.SuperCom.com.

NOTE TO INVESTORS: The latest news and updates relating to SPCB are available in the company’s newsroom at http://ibn.fm/SPCB

• A Fortune Business Insights report states that the global stainless steel market is projected to grow from $204.17 billion in 2022 to $298.85 billion in 2029
• Nickel is one of several components that form a powerful stainless steel alloy
• Canada Nickel is focused on sustainably producing the critical minerals needed for a low-carbon future

As the stainless steel market rebounds from COVID-19 slowdowns, Canada Nickel Company (TSX.V: CNC) (OTCQX: CNIKF) is working on advancing the next generation of high-quality, high-potential nickel-cobalt projects to deliver the metals needed to feed the high-growth stainless steel market. The company is particularly focused on sustainably producing the critical minerals needed for a low carbon future and operating in ways that support resilient local communities and minimize its environmental impacts (https://ibn.fm/tRr71).

A Fortune Business Insights report states that the global stainless steel market is projected to grow from $204.17 billion in 2022 to $298.85 billion in 2029, exhibiting a CAGR of 5.6% during the forecast period (https://ibn.fm/D8O9t); this increase comes after a decreasing demand during the global COVID-19 pandemic.

“Stainless steel comprises several components that fuse and form a powerful alloy,” the report observed. “The product is ecofriendly, corrosion resistant, long lasting, neutral alloy, strong and infinitely recyclable. Such properties make steel a perfect choice in several industries such as automotive, construction and electronic. The rapidly growing automotive industry is fueling the product demand. Furthermore, the product’s ability to resist corrosion coupled with rising manufacturing for recyclable material will further aid in propelling the market growth during the forecast timeframe.”

The report noted that other factors are also contributing to the increase in demand for stainless steel, including growing technological advancements to make sustainable stainless steel and global megatrends, such as rising mobility, urbanization, population and economic development, and increased climate change.

“Additionally, growing CO2 emissions worldwide led many steel products to develop a sustainable choice that could be durable and may be reused at the end of their life cycle,” the report stated. “Such factors, coupled with growing consumer preference to buy steel-based products, will create newer heights for the market to grow significantly.”

Deeply aware of its responsibility to operate in a sustainable manner, Canada Nickel Company is pursuing the development of processes to allow the production of net-zero carbon nickel, cobalt and iron products. In addition to ensuring its impact on the environment is minimal, the company is also committed to early, ongoing and accessible engagement specifically tailored to the interests and expectations of all project stakeholders, communities and Indigenous groups.

Canada Nickel intends to manage social, economic, environmental, cultural and human rights impacts by responding to community concerns, honestly and transparently, while working to directly optimize potential benefits of its projects.

Currently anchored by its wholly owned flagship Crawford Nickel-Cobalt Sulphide project in the heart of the prolific Timmins-Cochrane mining camp, Canada Nickel provides investors with leverage to nickel in low political-risk jurisdictions. The company is one of only a few new sources of potential supply outside Indonesia and China and brings industry-leading nickel expertise to the investment table.

For more information, visit the company’s website at www.CanadaNickel.com. 

NOTE TO INVESTORS: The latest news and updates relating to CNIKF are available in the company’s newsroom at https://ibn.fm/CNIKF

• GolfLync’s growth in members (15x in the past 4 months) is reminiscent of early-stage growth for companies like FaceBook (NASDAQ: META) and SnapChat (NYSE: SNAP)
• GolfLync’s membership conversion underscores its strength in the marketplace and ability to create innovative platform features users want
• GolfLync is growing because it understands how to create thriving online communities that connect its members together around their passion sport, GOLF

When it comes to new social media apps, the difference between hype and reality is seen in the numbers. GolfLync, a new and fast-growing social networking platform for golfers, has already garnered over 45,000 downloads, growing its member base more than 15x in just the past 4 months.

In comparison with other social media companies, GolfLync (available for download on the Apple App Store and the Google Play Store) has a top 25% conversion rate in its peer group (Social Networking) as shown in the Apple Store. GolfLync also has over 200 5-star reviews on the Apple App store.

GolfLync’s rapid expansion and conversion strength are bringing to mind the phenomenal early years of now social media icons such as Facebook and Instagram (NASDAQ: META), Pinterest (NYSE: PINS), and top social APPs like as Match (NASDAQ: MTCH), Hello Group (NASDAQ: MOMO), and SnapChat (NYSE: SNAP).

GolfLync

So what exactly is GolfLync? It’s the leading social media APP for golf. The platform’s intelligent discovery algorithms bring golfers together based on their golfing preferences and location, considering factors such as handicap and preferred playing style, and interests. By connecting like-minded golfers together around local and national communities, GolfLync has created a viral growth sensation few APPs achieve right off the launch pad.

In short, GolfLync’s many features, including private feeds, group chats, and personalized golf experiences, have set it apart as the go-to social network for golfers of all levels. Michael Quiel, Co-Founder of GolfLync, summed it up: “Our commitment to providing a user-friendly and feature-rich platform has driven the exceptional growth and engagement we are witnessing.”

You can download the GolfLync app for free using the following links:

• Android: GolfLync – Apps on Google Play
• iPhone: ‎GolfLync

For more information, visit the company’s website at www.GolfLync.com.

NOTE TO INVESTORS: The latest news and updates relating to GolfLync are available in the company’s newsroom at https://ibn.fm/GOLF

• Lexaria’s patented DehydraTECH(TM)-CBD achieved promising results for diabetes control and weight loss in animals during the pre-clinical animal study DIAB-A22-1
• The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7%
• Many drugs used to control diabetes have produced results in managing obesity, which Lexaria plans to leverage with its DehydraTECH(TM) technology

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, recently announced its intent to conduct a human clinical study to examine its patented DehydraTECH(TM)-processed cannabidiol (“CBD”) for diabetes control and weight loss. The company has already completed a pre-clinical diabetes study in animals, which supports its advancement to human trials for diabetes control and weight loss (https://ibn.fm/YFGIl).

Lexaria had announced in two prior press releases, on March 2 and June 16, that its pre-clinical diabetes study DIAB-A22-1 in obese diabetic-conditioned animals, that DehydraTECH-CBD had achieved the following:

• Lowered blood glucose levels by 19.9% (p<0.05)
• Lowered overall body weight by 7% sustained over eight weeks
• Witnessed a statistically significant increase in locomotor activity (p<0.05)
• Lowered triglyceride levels by more than 25% (p<0.007)
• Lowered blood urea nitrogen levels by 27.9% (p<0.001)

Based on these successful pre-clinical results, the management of Lexaria has decided to undertake a human diabetes clinical study to investigate whether any of these improvements will also be evidenced in humans. Lexaria is currently designing the study, which will be followed by submission to an independent review board to gain necessary approvals.

According to the Centers for Disease Control (“CDC”), managing one’s blood sugar levels is important to avoid diabetes-related conditions, including vision loss, heart disease, and kidney disease (https://ibn.fm/V90mU). Generic CBD studies, mainly conducted in animals, indicate that it may be ineffective in controlling blood sugar. Lexaria hopes to study whether the DehydraTECH-CBD formulation provides additional insight into human blood sugar control. The company is encouraged by DehydraTECH-CBD’s ability to reduce animal blood sugar levels and believes it warrants additional investigation.

The DehydraTECH technology is designed specifically for formulating and delivering lipophilic (fat-soluble) drugs and active pharmaceutical ingredients (“APIs”). DehydraTECH increases effectiveness and improves the way these APIs enter the bloodstream. The benefits of ingesting a DehydraTECH-enabled drug or consumer product include the following:

• Speeds up delivery with effects of the product felt in minutes
• Increases bioavailability due to its effectiveness in delivering a drug into the bloodstream
• Increases brain absorption, with animal testing evidencing higher drug quantities delivered across the blood-brain barrier
• Improved drug potency, with more of the drug available to the body, requiring lower dosages
• Reduced drug administration costs, meaning that lower dosages require less drug cost overall
• Mask unwanted tastes and reduces or eliminate the need for sweeteners

The company has also collaborated with the National Research Council (“NRC”), the Canadian government’s premier research and technology organization. DehydraTECH is covered by over 30 granted patents, with more pending worldwide. The patent protection includes formulations for specific delivery of cannabinoids, antiviral drugs, nicotine and more.

Many drugs used to control human blood glucose levels have shown promising weight loss results. The weight loss drug market was valued at $1.90 billion in 2021 and is expected to reach $13.26 billion by 2029, growing at a CAGR of 24.7% (https://ibn.fm/jN9UC). The market is growing due to the public’s growing interest in how obesity contributes to other health problems. Lexaria is positioning itself to potentially penetrate this market with its human-based clinical trial of DehydraTECH-CBD and diabetes control.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Ucore is engaged in the exploration for and separation and scalable production of REEs in Canada and the US
• Ucore Chairman and CEO Pat Ryan recently presented at the Critical Minerals Institute Summit II, where he discussed the risk mitigation strategies Western countries could execute to disrupt China’s dominance in the REE space
• On its part, and having identified has identified the need and demand for US-based REE refining and processing facilities, Ucore is working on developing, upscaling, and commercializing RapidSX(TM)
• RapidSX(TM) is the company’s transformative advanced column-based solvent extraction technique for separating both light and heavy REEs; it offers numerous benefits over the conventional solvent extraction technique
• Ucore is commissioning its 52-stage RapidSX(TM) Demonstration Plant in Kingston, Ontario

The government of China has consistently increased the total annual mining quota issued to producers of rare earth materials for the past five years: what started at 105,000 tons in 2017, doubled to 210,000 tons in 2022. Still, this uptrend shows no signs of easing, as country earlier this year set the first batch of rare-earth mining for 2023 at 120,000 tons, up by about 20% year-over-year (https://ibn.fm/uIRjY).

According to observers, this increase is due to the need to stabilize the prices of neodymium-iron-boron (“NdFeB”) permanent magnets amid an expected surge in demand as the country pushes for broader adoption of electric vehicles (“EVs”). (NdFeB magnets are critical to the functioning of clean energy technologies like electric vehicle (“EV”) motors and wind turbines, as well as defense systems.)

In response to the higher government quota, state-owned resource developers have announced plans to expand production. The country’s largest player in the rare earth space, China Northern Rare Earth Group, for instance, announced it would invest $1.1 billion (7.8 billion yuan) to convert an existing refining and processing facility into one of the largest in the world (https://ibn.fm/xx9sJ).

Such investments continue to support China’s status as a leader in the production and processing of rare earth elements (“REE”). In fact, according to the Critical Minerals Market Review 2023, published by the International Energy Agency (“IEA”), China accounts for 70% of production and 90% of processing (https://ibn.fm/Z5smw).

Worried about this dominance, which threatens, among others, national security and workforce development, the United States has stepped up its own mining operations and investments, becoming the world’s second-largest producer of REEs. Unfortunately, the country still lacks sufficient refining capacity, so it sends most of its output to China for processing before importing it back. But with China considering prohibiting exports of certain rare-earth magnet technology (https://ibn.fm/5idlI), this dependence poses a massive risk.

“Make no mistake, the battle lines are being drawn as global energy transition is upon us,” said Pat Ryan, Chairman and CEO of Ucore Rare Metals (TSX.V: UCU) (OTCQX: UURAF), in his speech delivered at the Critical Minerals Institute Summit II in June (https://ibn.fm/0N1iM). “Massive Chinese investments, especially in the rare earth supply chain, have created a steadfast monopoly. Nationalistic goals that have cornered resources and technology, seriously challenge the innovative and free market solutions of the US and allied countries. What risk-mitigating strategies can the West unilaterally execute for its own needs, allowing entrepreneurial ideas that have led global growth decade after decade to be refocused?”

Ryan’s speech, titled “Risk Mitigating for a North American Rare Earth Supply,” centered around an entrepreneurial theme that has long guided the operations of Ucore: identify demand and then respond with innovation. On its part, Ucore, a company engaged in the exploration for and separation and scalable production of REEs in Canada and the US, identified the need and demand for US-based REE refining and processing facilities and has, ergo, been focusing on developing, upscaling, and commercializing RapidSX(TM), its transformative advanced column-based solvent extraction technique for separating both light and heavy REEs.

RapidSX(TM) is at least three times more efficient than conventional solvent extraction (“CSX”) with a shorter overall processing time and lower construction and operation costs even though both share the same chemistry and unit operational steps. Plus, according to Ucore, the transformative technique results in REE products that are virtually indistinguishable from those made in facilities that use CSX. (CSX is used the world over to commercially separate REEs.)

Ucore is commissioning its 52-stage RapidSX(TM) Demonstration Plant in Kingston, Ontario, announcing June 29 the acquisition of its third feedstock, made up of mixed light REE chemical concentrate, for commissioning trials (https://ibn.fm/nhdsb). “The underway commissioning process at the RapidSX(TM) Commercialization and Demonstration Facility is the single most significant leap in the development of the RapidSX(TM) technology platform and, once completed, will open the pathway to direct commercialization and monetization of Ucore’s business model,” commented Mike Shrider, Ucore Vice President and COO, in the press release.

For more information, visit the company’s website at www.Ucore.com.

NOTE TO INVESTORS: The latest news and updates relating to UURAF are available in the company’s newsroom at https://ibn.fm/UURAF

• “Milestone” uplisting gives company greater access, exposure to the crucial U.S. investment market
• The uplisting has drawn increased focus, credibility to company’s two flagship projects
• Partnership with IBN designed to strengthen First Tellurium’s presence in growing essential metals market

First Tellurium (CSE: FTEL) (OTCQB: FSTTF) is taking key steps that reflect its growth and commitment to explore for — and provide — green and critical metals. Most recently the company announced that it had uplisting to the OTCQB venture market (https://ibn.fm/ZNYik) and had partnered with a veteran corporate communications consulting firm to strengthen the company’s news dissemination (https://ibn.fm/yE468).

Upgrading to OTCQB will provide enhanced access and exposure to the U.S. investor base, noted First Tellurium CEO and president. “Upgrading our OTC market listing has been an important, long-term goal of the company,” said Tyrone Docherty. “This milestone gives us far greater access and exposure to the crucial U.S. investment market, allowing us to attract a larger shareholder audience. The OTCQB is recognized as an established public market by the Securities and Exchange Commission, and it offers investors transparent, high-quality trading.”

The move was approved by the OTC Markets Group Inc. in June, and First Tellurium has been trading on the OTCQB under the symbol FSTTF ever since. The uplisting has drawn increased focus and credibility to the company’s two flagship projects: the Colorado-based Klondike tellurium-gold project and the British Columbia-based Deer Horn tellurium-gold-silver-copper project. These two projects are key to First Tellurium’s commitment to supply critical and essential metals, including tellurium, for North American markets. An essential element for the world’s transition to green energy, tellurium is used in high-efficiency cadmium telluride (“Cd-Te”) solar panels, next-generation lithium-ion batteries and thermoelectric devices, which change heat into energy.

In addition, First Tellurium has inked an initial six-month deal with corporate communications consulting experts IBN (InvestorBrandNetwork) to provide corporate communications consulting services and leverage the company’s enhanced outreach tools. The partnership is designed to increase news dissemination coverage and strengthen First Tellurium’s presence in the growing essential metals market.

IBN is a multifaceted financial news and publishing company servicing private and public entities. The company has almost two decades of experience supporting its more than 500 client partners improve communications and increase awareness within the investment community. In that time, IBN has created more than 60 trusted brands and works with 5,000-plus syndication partners to spread invaluable news to millions through its social media, newswire, newsletter, podcast and newsroom channels. “IBN is uniquely positioned to provide First Tellurium with the solutions needed to reach a wide audience of investors, journalists and the general public,” the company stated in the announcement.

First Tellurium’s unique business model is to generate revenue and value through mineral discovery, project development, project generation and cooperative access to untapped mineral regions in Indigenous territory with sustainable exploration.

For more information, visit the company’s website at www.FirstTellurium.com.

NOTE TO INVESTORS: The latest news and updates relating to FSTTF are available in the company’s newsroom at https://ibn.fm/FSTTF

• The company offers an approach that gives them a cost-saving edge over other producers in the market
• Preliminary discussions have been made to shortlist engineering firms capable of conducting the necessary SK-1300 technical reports for the company’s newest gold and Ammolite assets – with anticipated completion by the end of FY-2023
• GEMXX is participating in Regulation A financing, and interested investors, shareholders, institutions, and financiers, are urged to visit the company’s website for more information

GEMXX (OTC: GEMZ), a mine-to-market enterprise specializing in gold, gemstone, and jewelry production, recently announced that it has made significant progress in its efforts to finance its gold and Ammolite mining operations. During the last year, GEMXX has made significant strides in its growth plan, with increased shareholder value through acquiring materials and assets that support its goal of becoming fully integrated.

GEMXX has secured 75% of this fiscal year’s mining costs for the company’s gold and Ammolite initiatives. The involvement of new investors and strategic partners has strengthened the company’s financial position and supports its growth plan. This includes expanding GEMXX’s mine and process facility and increasing production to meet global product demand.

“Management is very excited to reach this financing milestone as it will allow the company to operate multiple mine assets at the same time,” said Richard Clowater, GEMXX President (https://ibn.fm/63mfz). “With the Snow Creek gold mine now in full production initial results have met all expectations, we look forward to having a gemstone and gold mine in production at the same time.”

GEMMX’s ambitious growth plan revolves around bolstering its market share through several key initiatives:

• First, GEMXX aims to strengthen its position in current markets by nurturing and expanding existing relationships with customers and partners.
• Second, the company plans to venture into untapped strategic markets by identifying and targeting new areas and establishing a presence in regions with promising growth opportunities.
• Thirdly, GEMXX envisions its growth through acquisitions, aiming to consolidate the market position and capitalize on synergies for enhanced success.

“Significant Strategic Partnerships are being formed that will allow the company to create more awareness of its market position and products it produces and sells around the world,” said Jay Maull, CEO of GEMXX (https://ibn.fm/VW5ll). “We endeavor to keep our stakeholders and shareholders updated as we hit milestones and sign agreements that will help the company reduce costs and increase revenues through partnerships, expansion, and new complementary product lines.”

GEMXX stands out due to its advantages in mining its gold reserves for use in jewelry production – an approach that gives the company a cost-saving edge over other producers in the market. Ammolite, similar to black opal, is a biogenic gem derived from the fossilized shells of Ammonites, a group of extinct marine nautiluses. Both avenues give GEMXX an advantage as a prominent player in the industry – standing out as a leader and producer of high-quality finished jewelry.

GEMXX has also completed preliminary discussions and has shortlisted engineering firms capable of conducting SK-1300 technical reports on both gold and Ammolite assets. Management anticipates the completion of the SK-1300 technical reports on the gold and Ammolite properties will produce a three-fold increase in the company’s proven resource base by the end of FY-2023.

The Company’s Form 1-A to raise up to $6,000,000 at $.40 per share pursuant to the Offering Statement is fully qualified. Shareholders, investors, institutions, and financiers interested in participating in the Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/iWTf5) or contact company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ